SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jenna who wrote (113505)9/7/2000 5:23:45 PM
From: Jenna  Read Replies (1) of 120523
 
MAXM Maxim Pharmaceuticals, Inc. another pharmie you might want to look at tomorrow. Chart is excellent with all moving averages rising and positive money flow. Volume was nearly double the average 65 day volume.

Maxim says FDA grants Maxamine priority status
STOCKHOLM, Sept 7 (Reuters) - Maxim Pharmaceuticals Inc (NasdaqNM:MAXM - news) said on Thursday the U.S. Food and Drug Administration (FDA) had granted its Maxamine skin cancer drug priority review status.

That means the FDA sees Maxamine, which counteracts a drop in melanoma patients' immune systems, as a potential therapeutic advance over existing therapies for the deadly disease, Maxim said in a statement.

The FDA usually takes action on drugs given a priority review within six months of acceptance of a new drug application (NDA), which Maxim submitted for Maxamine in July, it added.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News